Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial
-
- Monica M. Bertagnolli
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Craig J. Eagle
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Ann G. Zauber
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Mark Redston
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Aurora Breazna
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- KyungMann Kim
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Jie Tang
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Rebecca B. Rosenstein
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Asad Umar
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Donya Bagheri
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Neal T. Collins
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- John Burn
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Daniel C. Chung
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Thomas Dewar
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- T. Raymond Foley
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Neville Hoffman
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Finlay Macrae
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Ronald E. Pruitt
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- John R. Saltzman
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Bruce Salzberg
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Thomas Sylwestrowicz
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
-
- Ernest T. Hawk
- Authors' Affiliations: 1Brigham and Women's Hospital, and 2Massachusetts General Hospital, Boston, Massachusetts, 3Pfizer, Inc., 4Memorial Sloan-Kettering Cancer Center, New York, New York; 5University of Wisconsin, Madison, Wisconsin; 6CCS Associates, Inc., Mountain View, California; 7University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 8Harris Methodist Hospital, Ft. Worth, Fort Worth, Texas; 9Regional Gastroenterology Associates of Lancaster, Lancaster, Pennsylvania; 10Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 11The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 12Nashville Medical Research Institute, Nashville, Tennessee; 13Atlanta Gastroenterology Associates, Atlanta, Georgia; 14St. Paul's Hospital, University of Saskatchewon, Saskatoon, Saskatchewon; Canada, 15National Cancer Institute, Bethesda, Maryland; and 16M. D. Anderson Cancer Center, Houston, Texas
Abstract
<jats:title>Abstract</jats:title> <jats:p>The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer. The trial randomized 2,035 subjects to receive either placebo, celecoxib 200 mg twice daily, or celecoxib 400 mg twice daily. The primary study safety and efficacy analyses involved 3 years of treatment. The results showed significant antitumor effect but also indicated increased cardiovascular adverse events in patients treated with celecoxib compared with placebo. A total of 933 patients participated in an extension of the Adenoma Prevention with Celecoxib Trial, with a planned total treatment and surveillance duration of 5 years. Study medication was stopped early, resulting in a median treatment duration of 3.1 years for those with a year 5 colonoscopy. Patients treated on the placebo arm had a cumulative adenoma incidence of 68.4% over 5 years of observation. This figure was 59.0% (P < 0.0001) for those receiving low-dose celecoxib, and 60.1% (P < 0.0001) for those receiving high-dose celecoxib. The cumulative incidence of advanced adenomas over 5 years was 21.3% of those taking placebo, 12.5% (P < 0.0001) of those taking low dose celecoxib and 15.8% (P < 0.0001) of those taking high-dose celecoxib. Investigator reported treatment emergent adverse events were similar across all treatment groups for categories including renal and hypertensive events and gastrointestinal ulceration and hemorrhage events. For a category composed of cardiovascular and thrombotic events, the risk relative to placebo was 1.6 (95% confidence interval, 1.0, 2.5) for those using 200 mg twice daily celecoxib and 1.9 (95% confidence interval, 1.2, 3.1) for those using 400 mg twice daily celecoxib. Secondary analysis showed an interaction between a baseline history of atherosclerotic heart disease and study drug use with respect to cardiovascular and thrombotic adverse events (P = 0.004). These results confirm the inhibitory effect of celecoxib on colorectal adenoma formation, and provide additional safety data indicating an elevated risk for cardiovascular and thrombotic adverse events, particularly for patients with preexisting atherosclerotic heart disease.</jats:p>
Journal
-
- Cancer Prevention Research
-
Cancer Prevention Research 2 (4), 310-321, 2009-04-01
American Association for Cancer Research (AACR)
- Tweet
Details 詳細情報について
-
- CRID
- 1363670319019354368
-
- ISSN
- 19406215
- 19406207
-
- Data Source
-
- Crossref